Cilomilast for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4

Chest

Volumn 129, Issue 1, 2006, Pages 56-66

  Rennard, Stephen I ^a,e   Schachter, Neil ^b   Strek, Mary ^c   Richard, Kathy ^d   Amit, Ohad ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cilomilast; COPD; Phosphodiesterase 4; Phosphodiesterase 4 enzyme

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; NEDOCROMIL; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE; XANTHINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; LUNG FUNCTION; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; TREATMENT INDICATION;

EID: 33144469314     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.1.56     Document Type: Article

References (46)

1. Fletcher CM, Peto R, Tinker CM, et al. The natural history of chronic bronchitis and emphysema. Oxford, UK: Oxford University Press, 1976
2. Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep 2005; 53:17
3. Celli B, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
4. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
5. Mahler DA, Donahue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965
6. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087-1092
7. Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110:62-70
8. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105:1411-1419
9. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224
10. Van Noord JA, Bantje ThA, Elland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55:289-294
11. Casaburi R, Briggs D, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Chest 2000; 118:1294-1302
12. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double-blind, placebo-controlled study of fluticasone propionate in subjects with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
13. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909
14. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340:1948-1953
15. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild to moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353:1819-1823
16. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58:937-941
17. Torphy TJ. Phosphodiesterase isoenzymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157:351-370
18. Au B-T, Teixeira MM, Collins PD, et al. Effect of PDE4 inhibitors on zymosan-induced AL-8 release from human neutrophils: synergism with prostaglandins and salbutamol. Br J Pharmacol 1998; 123:1260-1267
19. Wooley ST, Weyman-Jones C, Young A. A comparison of the effect of PDE4 inhibitors on neutrophilia and cytokine expression in a murine model of LPS-induced lung inflammation [abstract]. Eur Respir J 2000; 16(suppl):539S
20. Barnette MS, Christensen SB, Essayan DM, et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998; 284:420-426
21. Liu Q, Fujimura M, Tachibana H, et al. Effect of a selective PDE4 inhibitor, SB207499, on airway cough hypersensitivity induced by allergic eosinophilic bronchitis [abstract]. Eur Respir J 2000; 16(suppl):539S
22. 4-induced mobilization of neutrophils in rabbits [abstract]. Am J Respir Crit Care Med 1999; 160:A90
23. Ammitt AJ, Hoffman RK, Amrani Y, et al. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by cyclic adenosine monopliosphate. Am J Respir Cell Mol Biol 2000; 6:794-802
24. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB207499), a second generation phosphodiesterase inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12:131-135
25. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168:976-982
26. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized, dose-ranging study. Lancet 2001; 358:265-270
27. American Thoracic Society. Standards for the diagnosis and care of subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:877-8121
28. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(suppl):398S-401S
29. American Thoracic Society. Standardization of spirometry. Am J Crit Care Med 1995; 152:1107-1136
30. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
31. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique; 1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198
32. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85(suppl):25-31
33. Barr JT, Schumacher GE, Freeman S, et al. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther 2000; 22:1121-1145
34. Jennrich RI, Schlucter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42:805-820
35. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-802
36. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121:1449-1455
37. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595-599
38. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
39. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:912-919
40. Szafranski W, Cukider A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Repir J 2003; 21:74-81
41. Vincken W, van Noord JA, Greefhorst AP, et al. Dutch/Belgian Tiotropium Stugy Group: improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209-216
42. Kohyama T, Liu X, Wen F-Q, et al. Cytokines modulate cilomilast response in lung fibroblasts. Clin Immunol 2004; 111:297-302
43. Kohyama T, Liu X, Wen F-Q, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of naïve collagen gels. Am J Respir Cell Mol Biol 2002; 26:694-701
44. Hogg JC, Chu F, Utokaparch S, et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645-2653
45. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166:675-679
46. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55:12-18